125 related articles for article (PubMed ID: 32661872)
1. Increasing the expression of programmed death ligand 2 (PD-L2) but not 4-1BB ligand in colorectal cancer cells.
Shakerin P; Sedighi Moghadam B; Baghaei K; Safaei Naraghi Z; Kamyab Hesari K; Asadzadeh Aghdaei H; Shokouhi Shoormasti R; Fazeli MS; Nourizadeh M
Mol Biol Rep; 2020 Aug; 47(8):5689-5697. PubMed ID: 32661872
[TBL] [Abstract][Full Text] [Related]
2. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors.
Pinto N; Park JR; Murphy E; Yearley J; McClanahan T; Annamalai L; Hawkins DS; Rudzinski ER
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28488345
[TBL] [Abstract][Full Text] [Related]
3. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
[TBL] [Abstract][Full Text] [Related]
4. PD-1 and PD-L2 expression predict relapse risk and poor survival in patients with stage III colorectal cancer.
Zengin M; Zergeroğlu S; Okcu O; Benek S
Cell Oncol (Dordr); 2021 Apr; 44(2):423-432. PubMed ID: 33469839
[TBL] [Abstract][Full Text] [Related]
5. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
[TBL] [Abstract][Full Text] [Related]
6. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1
Moreno-Cubero E; Subirá D; Sanz-de-Villalobos E; Parra-Cid T; Madejón A; Miquel J; Olveira A; González-Praetorius A; García-Samaniego J; Larrubia JR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093082
[TBL] [Abstract][Full Text] [Related]
7. PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.
Takamori S; Takada K; Toyokawa G; Azuma K; Shimokawa M; Jogo T; Yamada Y; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
Anticancer Res; 2018 Oct; 38(10):5897-5901. PubMed ID: 30275216
[TBL] [Abstract][Full Text] [Related]
8. Cholinergic signaling influences the expression of immune checkpoint inhibitors, PD-L1 and PD-L2, and tumor hallmarks in human colorectal cancer tissues and cell lines.
Kuol N; Godlewski J; Kmiec Z; Vogrin S; Fraser S; Apostolopoulos V; Nurgali K
BMC Cancer; 2023 Oct; 23(1):971. PubMed ID: 37828429
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 and PD-L2 expression in colorectal cancer.
Zeynep O; Funda C; Evrim Y; Deniz A; Bülent Y; Fatih YN
Indian J Pathol Microbiol; 2023; 66(1):31-37. PubMed ID: 36656207
[TBL] [Abstract][Full Text] [Related]
11. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression,
Morales-Betanzos CA; Lee H; Gonzalez Ericsson PI; Balko JM; Johnson DB; Zimmerman LJ; Liebler DC
Mol Cell Proteomics; 2017 Oct; 16(10):1705-1717. PubMed ID: 28546465
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
Front Immunol; 2020; 11():596825. PubMed ID: 33424844
[TBL] [Abstract][Full Text] [Related]
15. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
Front Immunol; 2019; 10():1644. PubMed ID: 31379843
[No Abstract] [Full Text] [Related]
16. Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy.
Huang KC; Chiang SF; Chen TW; Chen WT; Yang PC; Ke TW; Chao KSC
Sci Rep; 2020 Dec; 10(1):22330. PubMed ID: 33339860
[TBL] [Abstract][Full Text] [Related]
17. High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors.
Wolkow N; Jakobiec FA; Afrogheh AH; Pai SI; Faquin WC
Am J Ophthalmol; 2020 Dec; 220():128-139. PubMed ID: 32730911
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice.
Yassin M; Sadowska Z; Djurhuus D; Nielsen B; Tougaard P; Olsen J; Pedersen AE
Immunology; 2019 Sep; 158(1):35-46. PubMed ID: 31429085
[TBL] [Abstract][Full Text] [Related]
19. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39
Leem G; Park J; Jeon M; Kim ES; Kim SW; Lee YJ; Choi SJ; Choi B; Park S; Ju YS; Jung I; Kim S; Shin EC; Lee JY; Park SH
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335029
[TBL] [Abstract][Full Text] [Related]
20. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
Matsubara T; Takada K; Azuma K; Takamori S; Toyokawa G; Haro A; Osoegawa A; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
Ann Surg Oncol; 2019 Jun; 26(6):1925-1933. PubMed ID: 30815803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
